Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

No longer available 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 1Expanded_access 1

Sponsor

Cancer Type

Endocrine 2CNS 2

Conditions

Pheochromocytoma 2Neuroblastoma 2Thyroid Carcinoma, Anaplastic 1Neuroendocrine Tumors 1Neuroectodermal Tumors, Primitive 1Neoplasms 1Head and Neck Neoplasms 1Adrenocortical Carcinoma 1

Interventions

3-Iodobenzylguanidine 14Temozolomide 6lutetium Lu 177 dotatate 5gallium Ga 68 dotatate 4anlotinib 4Specimen Handling 4Everolimus 4Radiotherapy 3Phenoxybenzamine 3Magnetic Resonance Spectroscopy 3Doxorubicin 36-fluorodopamine 33-fluorobenzylguanidine 3pegfilgrastim 2olaparib 2fluorodopa F 18 2cabozantinib 2belzutifan 2Nivolumab 2Ifosfamide 2Granulocyte Colony-Stimulating Factor 2Fluorodeoxyglucose F18 2Filgrastim 2Doxazosin 2Dexmedetomidine 2Capecitabine 2Biopsy 2Axitinib 2Adrenalectomy 2177Lu-octreotide, DOTA(0)-Tyr(3)- 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Pheochromocytoma × pegfilgrastim × Endocrine × Clear all
NCT01850888 2025-12-18

MIBG for Refractory Neuroblastoma and Pheochromocytoma

Masonic Cancer Center, University of Minnesota

Phase NA Completed
15 enrolled
CNSEndocrine

Neuroblastoma, Pheochromocytoma

NCT03649438 2024-12-11

131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Relapsed/Refractory Neuroblastoma

University of Texas Southwestern Medical Center

No longer available
CNSEndocrine

Neuroblastoma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡